

E1 composed of a conjugate between an antibody and a cell toxin, fragments of antibodies and toxin, or recombinantly produced antibodies, toxins, immunotoxins or fragments thereof, wherein the antibodies are directed to epitopes on the antigen EGP2 expressed by the gene GA733 and to epitopes on the antigen expressed by the genes MUC1, MUC2 or MUC 3, respectively or a combination of these, and the toxin is Pseuctomonas exotoxin A.--

In the Claims

Please cancel claims ~~13~~, ~~18~~, ~~23~~ and ~~25~~. <sup>✓ ✓ ✓ ✓</sup> *Rule 1.126*

Please amend claims 1, 3, 6-8, ~~14-17~~, 19, and 21-22 to read as follows:  
*13-16, 18 20-21*

Sub F1  
E2  
1. (Amended) Method to kill breast cancer cells or other carcinoma cells expressing the same target antigens in a cell population selected from the group consisting of cells comprising nucleated cells in peripheral blood and bone marrow cells comprising CD-34<sup>+</sup> cells selected from the above nucleated cells, the method comprising:  
incubating the cell population with a combination of two or more immunotoxins, wherein each immunotoxin comprises a conjugate between an antibody or antigen binding antibody fragments and a cell toxin or active toxin fragments, or a recombinantly produced antibodies or antigen binding antibody fragments, and toxins or active toxin fragments, wherein the antibodies or antigen binding antibody fragments are directed to epitopes on the antigen EGP2 expressed by the gene GA733-2 and to epitopes on the antigen expressed by the MUC1 gene and the toxin is Pseudomonas exotoxin A.

E3  
Sub F2  
3. (Amended) The method according to claim 1, wherein the antibodies are MOC31 and BM7, or antigen binding fragments thereof.

E4  
6. (Amended) The method according to claim 1 wherein said incubating consists of administering the immunotoxins in vivo.

E5  
7. (Amended) The method according to claim 6, wherein the immunotoxins are administered systemically.

E5 8. (Amended) The method according to claim 6, wherein the immunotoxins are administered directly into a tumor or intrapleurally or intra-abdominally.

---

14. (Amended) The method of claim 1, wherein said incubating consists of administering the immunotoxins *ex vivo*.

15. (Amended) A method for killing breast cancer cells or other carcinoma cells expressing the same antigens in a cell population comprising nucleated peripheral blood cells or bone marrow cells, the method comprising

obtaining the population of cells that contains the breast cancer cells or other carcinoma cells expressing the same antigens;

contacting the population of cells *ex vivo* with two or more immunotoxins, wherein a first immunotoxin comprises a PE molecule conjugated to an antibody or an antibody fragment capable of binding an EGP2 antigen which is expressed by a GA733-2 gene and a second immunotoxin comprising a PE molecule conjugated to an antibody or an antibody fragment capable of binding an antigen encoded by the MUC1, MUC2, or MUC3 gene.

16. (Amended) The method according to claim 15, wherein the first immunotoxin comprises a PE molecule conjugated to a MOC31 antibody or an antigen-binding antibody fragment thereof, and the second immunotoxin comprises a PE molecule conjugated to a BM7 antibody or an antigen-binding antibody fragment thereof.

17. (Amended) The method according to claim 15, wherein the cell population is obtained from a cancer patient.

---

E7 19. (Amended) The method according to claim 15, wherein the cell population comprises CD34+ cells,

---

E8 21. (Amended) The method according to claim 1 wherein treatment of the cell population with the two or more immunotoxins causes relatively high toxicity to cancer or carcinoma cells and relatively low toxicity to CD34+ cells in the population.

22. (Amended) A method for killing breast cancer cells or other carcinoma cells expressing the same antigens in a patient, the method comprising

administering to the patient a therapeutically effective amount of two or more immunotoxins, wherein a first immunotoxin comprises a PE molecule conjugated to an antibody or an antibody fragment capable of binding an EGP2 antigen which is expressed by a GA733-2 gene and a second immunotoxin comprises a PE molecule conjugated to an antibody or an antibody fragment capable of binding an antigen encoded by the MUC1, MUC2, or MUC3 genes.

1. Please add the following new claims:

E9 Rule 1.124 ~~25~~ 26. (New) The method according to claim 7, wherein the immunotoxins are administered systemically to kill malignant cells.

~~26~~ 27. (New) The method according to claim 26, wherein the malignant cells have spread to blood or bone marrow.